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Background: The La-related protein 1 (LARP1) has been found to be a RNA binding protein and was related to
spermatogenesis, embryogenesis and cell-cycle progression. The aim of this study was to investigate the prognostic
value of LARP1 in hepatocellular carcinoma (HCC).
Methods: LARP1 expression was examined in 15 HCC cell lines and 272 clinical specimens using real-time PCR,
immunohistochemistry (IHC) and western blot analysis (WB). LARP1 expression was also studied in 6 paired HCC
lesions and the adjacent non-cancerous tissue samples. Statistical analyses were applied to derive association
between LARP1 expression scores and clinical characters as well as patient survival.
Results: mRNA and protein levels of LARP1 were higher in HCC cell lines and HCC lesions than in normal liver
epithelial cells and the paired adjacent noncancerous tissues. LARP1 expression was correlated to survival time, vital
status, tumor size and Child-Pugh score. Overall survival analysis showed HCC patients with high LARP1 expression
level had lower survival rate (P < 0.01). Importantly, this correlation remained significant in patients with early-stage
HCC or with normal serum AFP level.
Conclusions: LARP1 protein may represent a promising biomarker for predicting the prognosis of HCC, including in
early-stage and AFP-normal patients.
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Hepatocellular carcinoma (HCC) is one of the most com-
monly diagnosed cancers and the third most common
cause of cancer mortality worldwide [1]. Despite great ad-
vances in surgical and medical management of the disease,
relapse and metastasis are frequently observed in the
clinic, and the long-term prognosis of patients with HCC
is unsatisfactory. The development and progression of
HCC is a multistage process involves molecular pathways
and genetic abnormal changes [2]. No specific signature of
liver cancer gene expression has been reported to allow
for patient-tailored therapy strategies. Hence, it is of great
clinical value to further identify effective early markers for* Correspondence: happyxiechan@gmail.com; gaozl@yahoo.com.cn
1Department of Infectious Diseases, The Third Affiliated Hospital of Sun
Yat-Sen University, 600# TianHe Road, Guangzhou 510630, Guangdong
Province, China
2Key Laboratory of Tropical Disease Control, Ministry of Education, Sun
Yat-Sen University, Guangzhou, Guangdong Province, China
Full list of author information is available at the end of the article
© 2013 Xie et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe diagnosis and prognosis of the disease as well as novel
therapeutic targets.
The progression of HCC is thought to involve the de-
regulation of genes that are critical to cellular processes
such as cell cycle control, cell growth, apoptosis, and cell
migration and spreading. Clinically, prediction of prog-
nosis plays an essential role in the assessment of HCC
patients and optimal therapeutic options. As an increas-
ing number of early-stage, small HCC nodules (< 3 cm)
in patients with normal serum level of alpha fetal protein
(AFP), a most commonly used diagnostic biomarker for
HCC, prediction of prognosis of these patients represents
a major challenge in the clinic [2]. While tremendous ef-
fort has been made in identifying effective indicators for
the prognostic prediction of these HCC, the availability of
clinically applicable biomarkers remains limited. La-related
protein 1 (Larp1) was first described in Drosophila and
shown to be required for spermatogenesis, embryogenesis
and cell cycle progression [3-5]. Phenotypically, loss of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological characteristics of clinical
samples and expression of LARP1 in liver cancer
Characteristics No. Patients %
Age (years) ≤50 159 41.5
>50 113 58.5
Gender Male 244 89.7
Female 28 10.3
TNM classification I 16 5.9
II 195 71.7
III 61 22.4
HBsAg Positive 225 87.5
Negative 32 12.5
AFP ≥400 ng/ml 100 38.0
<400 ng/ml 163 62.0
Tumor size >3 cm 228 84.4
≤3 cm 42 15.6
Tumor number >1 93 34.4
= 1 177 65.6
Child-pugh class A 264 97.1
B 8 2.9
Vital status (at follow-up) Alive 152 55.9
Death due to liver cancer 120 44.1
Expression of LARP1 High expression 101 37.1
Low expression 171 62.9
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formation of migratory lamellipodia in cell [6]. These data
raise exciting questions about the role of Larp1 in mRNA
translation and cell migration, and suggest Larp1 may have
relevance in a number of conditions in which these pro-
cesses are disrupted, such as in protein production and
cancer.
In our current report, immunohistochemical analysis
was performed to investigate the potential prognostic util-
ity of LARP1 in a validation cohort of HCC in comparison
with non-neoplastic liver tissues, including HCC patients
with normal serum AFP level of early stage. Our data sug-




HCC cell lines, including QGY-7703, HCCC-9810, PLC/
PRF5, SMMC-7721, Hep3B, HepG2, HuH7,HepG-2215,
Bel-7402, QGY-7701, Bel-7404, HCCLM3, HCCLM6,
MHCC97H and MHCC97L, were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (FBS)
(Invitrogen). Immortalized normal liver epithelial cells,
THLE3, were maintained in bronchial epithelial growth
medium (Lonza Cologne GmbH, Walkersville, MD), with
5 ng/ml epidermal growth factor, 70 ng/ml phosphoetha-
nolamine and 10% FBS, at 37°C in a humidified atmos-
phere containing 5% CO2.
Patient cohorts
A total of 272 cases of paraffin-embedded HCC samples
which had been clinically and histologically diagnosed at
the Sun Yat-Sen University Cancer Center (Guangzhou,
China) from 1996 to 2004. Six fresh HCC tissue samples,
together with their paired adjacent non-cancerous tissues
from each patient in the third affiliated hospital of
Guangzhou medical university, were collected from HCC
curative resection surgery from 2011 to 2012, snap frozen
and stored at −80°C until use for experimental purposes.
For the use of these clinical materials for research pur-
poses, prior patients’ consents and approval from the
Institutional Research Ethics Committee were obtained.
This cohort of patients with HCC included 244 (89.7%)
men and 28 (10.3%) women, with a median age of 49 years,
and their clinico-pathological characteristics are summa-
rized in Table 1. Tumor stages were defined according
to the 2002 American Joint Committee on Cancer/
International Union against Cancer tumor/lymph node me-
tastasis/distal metastasis (TNM) classification system.
Hepatitis B virus (HBV) infection was diagnosed when
HBV surface antigen (HBsAg) was detected by ELISA in
the serum. In addition, for Western blot analysis, three
normal liver tissues were obtained from the patientsundergoing resection of hepatic hemangiomas at the
Department of Hepatobiliary Surgery in 2011, the First
Affiliated Hospital of Sun Yat-sen University, in accord-
ance with rules and regulations concerning ethical issues
on research use of human subjects in China. Follow-up
visits were scheduled postoperatively at intervals of one
month for six months, bimonthly for six months, quar-
terly for six months, and semiannually for life.
RNA extraction, reverse transcription (RT) and real-time
PCR
Total RNA from cultured cells was extracted using the
Trizol reagent (Invitrogen, Carlsbad, CA) as the manufac-
turer instructed. cDNAs were amplified and quantified in
ABI Prism 7500 Sequence Detection System (Applied
Biosystems, Foster City, CA) using dye SYBR Green I
(Invitrogen, Carlsbad, CA). The LARP1 primers designed
using the Primer Express v 2.0 software (Applied Biosys-
tems) are provided as following: forward: 5′- GCTGTT
TAGGAACAGCTGCC -3′ and reverse: 5′- CCACAGG
TGACAGGGAGAAG-3′. Expression data were normal-
ized to the geometric mean of housekeeping gene
GAPDH (forward: 5′-ACCACAGTCCATGCCATCAC-3′
and reverse: 5′-TCCACCACCCTG TTGCTGTA -3′) to
control the variability in expression levels and calculated
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threshold cycle for each transcript.Western blot
Total protein was prepared using the cell total protein ex-
traction kits according to the manufacturer’s instruction
(Millipore, Billerica, MA). Western blot was performed
according to standard methods, using an anti-LARP1
antibody (Abcam, UK). Blotted membranes were stripped
and re-probed with an anti-GAPDH antibody (Sigma,
Saint Louis, MI) as a loading control.Immunohistochemistry (IHC)
The IHC procedure for LARP1 and scoring of LARP1
expression were performed as previously reported [7].
IHC staining was quantitatively analyzed with the
AxioVision Rel.4.6 computerized image analysis sys-
tem assisted with the automatic measurement pro-
gram (Carl Zeiss, Oberkochen, Germany). Briefly, the
stained sections were evaluated at 200x magnification,
and ten representative staining fields of each section
were analyzed to produce Mean Optical Density value
(MOD), which represented the strength of staining
signals as measured per positive pixels. The MOD
data were statistically analyzed using t-test to com-
pare the average MOD difference between different
groups of tissues. An optimal cutoff value was identi-
fied: the staining index score of > 6 was used to define
tumors as high LARP1 expression and ≤ 6 as low ex-
pression of LARP1.Gene Expression Omnibus database analysis
Gene Expression Omnibus database (GEO GSE25097)
was used in the analysis of relationship of LARP1 expres-
sion and HCC.Statistical analysis
All statistical analyses were carried out using the
SPSS v. 13.0 statistical software packages (SPSS,
Chicago, IL). Spearman’s correlation test was applied
to analyze the correlation between LARP1 expression
and clinic pathological characteristics. Survival curves
were plotted by the Kaplan-Meier method and com-
pared using the log-rank test. Independent prognostic
factors were estimated by the Cox proportional haz-
ards stepwise regression model. We first used SPSS
statistic software to perform the Univariate analysis of
each variance and found the factors which is signifi-
cant different in the two groups and then perform
the multivariate analysis. All P values were two-sided.
A P value of less than 0.05 was considered statisti-
cally significant in all cases.Results
Upregulation of LARP1 in HCC cell lines and liver cancer
lesions
Western blot and real-time PCR analyses revealed LARP1
was highly expressed in all fifteen HCC cell lines tested
than that in immortalized normal liver epithelial cells
THLE3 (Figure 1A and B). To determine whether LARP1
upregulation found in liver cancer cell lines was related to
clinical biochemical indicators, Western blot analysis was
performed with 6 paired HCC tissues and non-cancerous
tissues adjacent to HCC tumors. As shown in Figure 1C,
LARP1 protein expressed was higher in all six HCC sam-
ples, displaying more than 3-fold increase of LARP1
expression as compared that in the adjacent non-cancer
tissue samples. In agreement with the result of Western
blot assay, immunohistochemical analysis also showed
LARP1 upregulation in HCC lesions (Figure 1D).
Association between LARP1 expression and clinical
features of liver cancer
To determine the clinical significance of LARP1, the cor-
relation between the clinicopathological features of HCC
and LARP1 expression was investigated in a retrospective
cohort of 272 HCC cases by IHC, including 16 cases of
stage I (5.9%), 195 cases of stage II (71.7%) and 61 cases of
stage III (22.4%) , based on the TNM staging. In the
cohort, 87.5% patients had HBV infection. LARP1 expres-
sion in 272 enrolled patient samples was determined as
strong in 101 cases (37.1%) and weakly positive or nega-
tive in 171 cases (62.9%) (Table 1). As shown in Figure 2A,
the immunoreactivity of LARP1 was detected at variable
levels and localized in the cellular nucleus and plasma.
The LARP1 protein expression was generally weak in
adjacent non-cancer tissue samples and early stage HCC
(TNM stages I and II), but strong in later stage HCC
(TNM stages III) tissues. Quantitative analysis of the
IHC staining indicated that LARP1 expression in clinical
stage I–III primary tumors was statistically higher than
that in adjacent non-cancer tissue samples (P < 0.05,
Figure 2B). Spearman analysis revealed correlations be-
tween LARP1 and Tumor size (P P < 0.05), survival time
(P < 0.01), Child-Pugh (P < 0.01) and vital status (P < 0.01)
(Table 2). No significant associations between expression
of LARP1 and other clinicopathological parameters such
as age, HBsAg status, tumor size and number of tumor
nodules (Table 2), further suggesting a correlation of
LARP1 expression with HCC clinical staging and patient
survival. To confirm the result of the relationship of
LARP1 with HCC, we analysis the different expression of
LARP1 in a Microarray data which have been depos-
ited in the Gene Expression Omnibus database (GEO
GSE25097). This database included mRNA information
of tissues of 6 healthy peoples, 40 liver cirrhosis pa-
tients, 243 non-tumor tissues from HCC patients and
Figure 1 Expression of LARP1 is elevated in HCC. (A-B) Expression of LARP1 protein (A) and mRNA (B) in normal human liver epithelial cells
(THLE3) and cultured liver cancer cell lines. GAPDH was used as a loading control. (C-D) Western blot (C) and IHC (D) analysis of LARP1 protein in
each of the primary liver cancer tissue (T) and adjacent non-cancerous tissues (ANT) samples taken from the same patient. Error bars represent SD
from three independent experiments. * P < 0.05.
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expression of LARP1in HCC patients is higher than that
in healthy person. LARP1 is highly expressed in HCC than
in adjacent non-tumor tissues (Figure 2C). But the LARP1
expression of liver cirrhosis patients did not change. And
the LARP1 expression of adjacent non-tumor tissues was
lower in the healthy persons. The meaning of the decrees
of LARP1 in adjacent non-tumor tissues is wildly un-
known and more deeper research needed to clarify the
mechanism of LARP1 in HCC develop.
Univariate and multivariate analyses of the prognostic
power of LARP1
To identify variables with potential prognostic signifi-
cance in HCC patients, univariate analysis for each vari-
able was performed in relation to the survival time. Inour univariate analysis, stepwise inclusion of variables in
the model showed that significant prognostic factors
included LARP1 level, tumor size, tumor number,
Child-Pugh class and TNM classification. Moreover,
multivariate analysis demonstrate that tumor size, tumor
number, Child-Pugh class and LARP1 expression level
are indeed predictive of the overall survival (OS) of HCC
patients (Table 3).
Prognostic values of LARP1 in different HCC subgroups
To further demonstrate the value of LARP1 expression
in predicting survival of HCC patients, multiple analysis
methods were performed in this study. Firstly, as shown
in Figure 2D, Kaplan-Meier and log-rank survival tests
suggested that low- and high-LARP1 expression in HCC
patients were associated with different survival time,
Figure 2 Overexpression of LARP1 in archived HCC. (A) Representative IHC analyses of LARP1 expression in normal liver tissue (NL) and HCC
specimens of different TNM stages. Statistical quantification of the average of the mean absorbance ( MOD) values of LARP1 staining between
normal liver tissue (NL) and HCC specimens of different TNM stages. (B) MOD of LARP1 staining increases as HCC progresses to a higher clinical
stage. (C) Gene Expression Omnibus database (GEO GSE25097) analysis showed different mRNA expression in the indicated tissues.
(D) Kaplan–Meier curves with univariate analyses (log-rank) for patients with low- versus high-LARP1 expression.
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Table 2 Spearman analysis of correlation between LARP1
and clinicopathological factors
Variables LARP1 expression level
Spearman Correlation P Value
Survival time - 0.317 0.000






Tumor number 0.045 0.458
Tumor size 0.137 0.023
Child-Pugh 0.163 0.007
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HCC lesions surviving much longer that those with high
LARP1 expression (P < 0.01). Interestingly, these patients
with different OS could not be distinguished by conven-
tional AFP test. While for the whole study cohort, the
OS rates at 3, 5 and 8 years, respectively, were 46%, 37%
and 33%, patients with high LARP1 protein levels had a
significantly lowered 3, 5, 8-year survival rate than those
with low LARP1 protein levels (14%, 10%, 7% vs 68%,
57%, 57%, respectively, P < 0.05).
A validation cohort was employed to further evaluate
the prognostic value of LARP1 for specific subgroups of
patients. As shown in Figure 3, the LARP1 levels were
significantly associated with OS in patients with early-
stage HCC, and such a predictive power was also ob-
served in patients without AFP elevation. In the subgroup
of patients with low AFP (< 400 ng/ml), LARP1-low
expression was associated with a 5-year OS rate of 54%,
in contrast to 13% for the high-LARP1 group (P < 0.01,
Figure 3A). Then we used different cutoff levels of AFP
(400 ng/ml, 200 ng/ml and 100 ng/ml, respectively) to
subgroup the 272 HCC patients and evaluated the prog-
nostic significance of LARP1in the patient subgroups.Our
data suggested that AFP cut-off values of 200 ng/ml or
100 ng/ml) were significantly predictive of patient
survival, whereas AFP = 400 ng/ml was not a prognostic
cut-off. However, in all above HCC patient subgroups, theTable 3 Univariate and multivariate analyses of various progn
Cox-regression analysis
Univariate analysis
Relative risk 95% confidence interval
Tumor size 1.061 1.024-1.101
Tumor number 1.116 1.051-1.184
LARP1 1.280 1.205-1.395
Child-Puge 1.562 1.322-1.847level of LARP1 was more sensitive to predict the progno-
sis of HCC patients than AFP. As shown in the subgroup
of AFP level less than 200 or 100 ng/ml, LARP1 was able
to separate patients with different OS rates as well
(Figure 3B and C).
In another group of HCC patients whose survival has
been difficult to predict in the clinic, namely, those with
tumor sizes smaller than 3 cm in diameter, the 5-year
survival rate was 75% in the low LARP1 group, as op-
posed to 23% for patients exhibiting high LARP1 expres-
sion (P = 0.005, Figure 4A). In the clinical subgroup with
one single HCC tumor nodule, the 5-year survival rates
were 63% and 9%, respectively, for low - or high -LARP1
expression patients (P < 0.01, Figure 4B). In early-stage
HCC patients (TNM stages I-II), low -LARP1 expression
patients revealed a 5-year survival rate of 53%, whereas
the survival rate decreased to 13% in the high LARP1
group (P < 0.01, Figure 4C). Taken together, therefore,
our data suggest a potentially promising prognostic
value of LARP1 for HCC patients in various clinical sub-
groups that otherwise could have been difficult for sur-
vival prediction.
Discussion
In the present study, a cohort of patients (n = 272) were
examined for LARP1 expression. Consistent results de-
rived from three different assays strongly suggest a correl-
ation between LARP1 level and the clinical outcome of
HCC. Identification of LARP1 as a prognostic biomarker
for HCC in our present study provides new opportunities
in the clinic for prediction of patient survival. The findings
that high LARP1 expression level is present in HCC cell
lines and clinical lesions, as well as its correlation with the
clinical staging of HCC, lay a foundation for developing
this immunologically and pathologically detectable mol-
ecule into a clinically applicable approach to improved pa-
tient management based on more accurate judgment on
disease prognosis.
LARP1 is on chromosome 5q33.2 possesses a signature
La motif, which is an ancient RNA-binding domain, plus a
second conserved motif. LARP1 appears to bind RNA
in vitro via both the La motif and the LARP1 domain [8].
Five LARP proteins exist in the human genome [9].
LARP1 regulates negatively RAS-MAPK pathway and isostic parameters in patients with liver cancer by
Multivariate analysis
P Relative risk 95% confidence interval P
0.001 1.056 1.019-1.094 0.002
0.000 1.151 1.075-1.232 0.000
0.000 1.252 1.170-1.339 0.000
0.000 1.219 1.013-1.466 0.036
Figure 3 Kaplan-Meier analysis of OS in 272 patients based on LARP1 expressions in HCC subgroups of different AFP levels. (A) Using
AFP level (400 ng/ml) as the cut-off could not separate patients with different OS rates in the study cohort (left). By contrast, LARP1 expression
level predicted different OS rate in the subgroup of AFP < 400 ng/ml and AFP≥ 400 ng/ml. (B) OS rate of patients with AFP <200 ng/ml and
AFP≥ 200 ng/ml, respectively. (C) OS rates of patients with high- or low- LARP1 expression when further divided into AFP < 100 ng/ml and
AFP≥ 100 ng/ml subgroups.
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tosis [6,8]. LARP1 protein colocalizes with P bodies [8]
which function in RNA degradation. But the role of LARP1
in HCC is unclear. Our current study employed large num-
bers of patients in independent cohorts (n = 272). The
consistency of the results of three assay methods (RT-PCR,
immunoblotting and immunohistochemistry) and therepeat validations in the test as well as the independent val-
idation cohort, provide with essential, reliable evidence for
the clinical significance of LARP1 as a prognostic bio-
marker for HCC.
AFP is most commonly employed in the clinic for HCC
screening and as an important predictor for patient survival
after tumor resection [10-12] The diagnostic sensitivity of
Figure 4 Kaplan-Meier analysis of OS in 272 patients based on LARP1 expressions in HCC clinical subgroups. (A) When patients were
divided into subclinical groups according to tumor size, probabilities of survival with either HCC lesion diameter > 3 cm (left) or ≤3 cm (right), as
well as high- and low-LARP1 expression, distinguishes lower and higher, respectively, SO rates. (B) OS in patients with single tumor lesion and
multi-tumor lesion. (C) OS rates in patients subgrouped into TNM stages I-II (left) and TNM stages III (right) as differentiated by high- or
low-LARP1 expression.
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alone, leading to the unsatisfying reality that a large number
of HCC patients without AFP elevation are missed and sub-
sequently progress to late stage-HCC before becoming clin-
ically symptomatic and detectable [11]. Due to its low
sensitivity in identifying new HCC cases that have not been
detected by imaging technology previously, AFP has beenshown to be only marginally effective in specific patient
populations [11]. Indeed, only 38.0% of HCC patients in
our study cohorts are AFP-positive. By contrast, in the pa-
tient group in which AFP level was not predictive for prog-
nosis, LARP1 appeared to be indicative of survival time
lengths that are differential among the patients. Thus, our
study has exhibited the potential value of LARP1 in
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levels or in the early-stage HCC group, which would have
been difficult using currently clinically available surrogate
biomarkers.
Studies have shown that for HCC early diagnosis and
treatment strategies, such as surgical resection and liver
transplantation, there is a longer survival time associated
with patients who have a single HCC tumor nodule <
3 cm in diameter, or with patients carrying no more than
3 nodules with each smaller than 3 cm in diameter, giving
rise to a reported 5-year survival of 50 to 70% [13,14].
Using biomarkers to identify patients with a highest risk
of developing worse prognosis may thus reduce mortality
and medical costs. It is particularly noteworthy that in our
test cohort, the patients with early HCC (TNM stages I-II)
display a significantly higher levels (3–5 folds increase) of
LARP1 in the HCC lesions than that in the normal liver
tissue, and as the disease progresses to later stages, the
LARP1 level increases further. In our validation cohort,
early-stage (TNM stages I-II, tumor size less than 3 cm,
single tumor nodule) HCC patients with low level of
LARP1 protein immunostained also display a relative high
OS than those diagnosed with late-stage HCC who carry
high levels of LARP1 expression. In consistence with our
observation, LARP1 has been mechanistically shown to
promote cell invasion and metastasis [6]. High potential of
vascular invasion and metastasis is often the main bio-
logical basis for the poor prognosis of HCC [14]. Thus,
these characters of LARP1 thus warrant efforts to further
explore the potential of LARP1 to become a promising
biomarker for identifying patients with good prognosis
after surgical excision in early stages. Inclusion of meta-
static cases in future studies will help address whether a
high-level expression of LARP1 in early-stage HCC pa-
tients may have the potential to progress to poor survival.
Several systems are available to classify HCC. Among
them, the International Union Against Cancer’s TNM
staging is one of the most prevalent. Although the TNM
system has successfully graded patients on their progno-
sis according to clinicopathological variables, it is still
limited in providing predictive information key to deter-
mining therapeutic strategies in subgroups of HCC
patients, such as, prediction the prognosis of early-stage
HCC. Thus, our current finding has provided evidence
that the higher expression of LARP1 in HCC may be im-
portant for the detection of an aggressive phenotype or a
phenotype predicting poor prognosis. We believe that
the use of LARP1 protein as a diagnostic biomarker of
HCC could improve the prospects of the early detection
of HCC; and that an improved rate of detection would
have important prognostic implications for patients with
HCC. It is necessary to point out that our current study
is of the retrospective nature and the number of patients
with HCC lesions smaller than 3 cm was small. Clearly,further prospective studies designed to include a larger
number of HCC lesions smaller than 3 cm and pa-
tients with metastasis are needed to validate the con-
clusions of this study. Moreover, it would be of great
clinical value to determine the relationships of LARP1
with other signalling molecules and pathways which
help us to better understand the molecular pathogen-
esis of these tumors and develop more effective tar-
geted therapeutic strategies.
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